Cargando…

Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation

The eyes are the window to the world and the key to communication, but they are vulnerable to multitudes of ailments. More serious than is thought, corneal infection by herpes simplex viruses (HSVs) is a prevalent yet silent cause of blindness in both the paediatric and adult population, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Manisha, Choudhury, Hira, Abdul-Aziz, Azila, Bhattamisra, Subrat Kumar, Gorain, Bapi, Su, Jocelyn Sziou Ting, Tan, Choo Leey, Chin, Woon Yee, Yip, Khar Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821943/
https://www.ncbi.nlm.nih.gov/pubmed/33374925
http://dx.doi.org/10.3390/pharmaceutics13010001
_version_ 1783639530746675200
author Pandey, Manisha
Choudhury, Hira
Abdul-Aziz, Azila
Bhattamisra, Subrat Kumar
Gorain, Bapi
Su, Jocelyn Sziou Ting
Tan, Choo Leey
Chin, Woon Yee
Yip, Khar Yee
author_facet Pandey, Manisha
Choudhury, Hira
Abdul-Aziz, Azila
Bhattamisra, Subrat Kumar
Gorain, Bapi
Su, Jocelyn Sziou Ting
Tan, Choo Leey
Chin, Woon Yee
Yip, Khar Yee
author_sort Pandey, Manisha
collection PubMed
description The eyes are the window to the world and the key to communication, but they are vulnerable to multitudes of ailments. More serious than is thought, corneal infection by herpes simplex viruses (HSVs) is a prevalent yet silent cause of blindness in both the paediatric and adult population, especially if immunodeficient. Globally, there are 1.5 million new cases and forty thousand visual impairment cases reported yearly. The Herpetic Eye Disease Study recommends topical antiviral as the front-line therapy for HSV keratitis. Ironically, topical eye solutions undergo rapid nasolacrimal clearance, which necessitates oral drugs but there is a catch of systemic toxicity. The hurdle of antiviral penetration to reach an effective concentration is further complicated by drugs’ poor permeability and complex layers of ocular barriers. In this current review, novel delivery approaches for ocular herpetic infection, including nanocarriers, prodrugs, and peptides are widely investigated, with special focus on advantages, challenges, and recent updates on in situ gelling systems of ocular HSV infections. In general congruence, the novel drug delivery systems play a vital role in prolonging the ocular drug residence time to achieve controlled release of therapeutic agents at the application site, thus allowing superior ocular bioavailability yet fewer systemic side effects. Moreover, in situ gel functions synergistically with nanocarriers, prodrugs, and peptides. The findings support that novel drug delivery systems have potential in ophthalmic drug delivery of antiviral agents, and improve patient convenience when prolonged and chronic topical ocular deliveries are intended.
format Online
Article
Text
id pubmed-7821943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78219432021-01-23 Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation Pandey, Manisha Choudhury, Hira Abdul-Aziz, Azila Bhattamisra, Subrat Kumar Gorain, Bapi Su, Jocelyn Sziou Ting Tan, Choo Leey Chin, Woon Yee Yip, Khar Yee Pharmaceutics Review The eyes are the window to the world and the key to communication, but they are vulnerable to multitudes of ailments. More serious than is thought, corneal infection by herpes simplex viruses (HSVs) is a prevalent yet silent cause of blindness in both the paediatric and adult population, especially if immunodeficient. Globally, there are 1.5 million new cases and forty thousand visual impairment cases reported yearly. The Herpetic Eye Disease Study recommends topical antiviral as the front-line therapy for HSV keratitis. Ironically, topical eye solutions undergo rapid nasolacrimal clearance, which necessitates oral drugs but there is a catch of systemic toxicity. The hurdle of antiviral penetration to reach an effective concentration is further complicated by drugs’ poor permeability and complex layers of ocular barriers. In this current review, novel delivery approaches for ocular herpetic infection, including nanocarriers, prodrugs, and peptides are widely investigated, with special focus on advantages, challenges, and recent updates on in situ gelling systems of ocular HSV infections. In general congruence, the novel drug delivery systems play a vital role in prolonging the ocular drug residence time to achieve controlled release of therapeutic agents at the application site, thus allowing superior ocular bioavailability yet fewer systemic side effects. Moreover, in situ gel functions synergistically with nanocarriers, prodrugs, and peptides. The findings support that novel drug delivery systems have potential in ophthalmic drug delivery of antiviral agents, and improve patient convenience when prolonged and chronic topical ocular deliveries are intended. MDPI 2020-12-22 /pmc/articles/PMC7821943/ /pubmed/33374925 http://dx.doi.org/10.3390/pharmaceutics13010001 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pandey, Manisha
Choudhury, Hira
Abdul-Aziz, Azila
Bhattamisra, Subrat Kumar
Gorain, Bapi
Su, Jocelyn Sziou Ting
Tan, Choo Leey
Chin, Woon Yee
Yip, Khar Yee
Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title_full Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title_fullStr Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title_full_unstemmed Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title_short Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation
title_sort advancement on sustained antiviral ocular drug delivery for herpes simplex virus keratitis: recent update on potential investigation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821943/
https://www.ncbi.nlm.nih.gov/pubmed/33374925
http://dx.doi.org/10.3390/pharmaceutics13010001
work_keys_str_mv AT pandeymanisha advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT choudhuryhira advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT abdulazizazila advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT bhattamisrasubratkumar advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT gorainbapi advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT sujocelynsziouting advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT tanchooleey advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT chinwoonyee advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation
AT yipkharyee advancementonsustainedantiviraloculardrugdeliveryforherpessimplexviruskeratitisrecentupdateonpotentialinvestigation